Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$914.06 | -$0.06 | Beat |
| May 15, 2026 | -$914.06 | -$0.04 | Beat |
| Mar 11, 2026 | – | -$0.03 | |
| Nov 13, 2025 | – | -$0.01 | |
| Aug 14, 2025 | – | -$0.02 | |
| May 15, 2025 | – | -$0.16 |